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SUMMARY 38 
Background & aims: Urolithins are microbial metabolites produced after consumption of 39 
ellagitannincontaining foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing 40 
phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-41 
B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), 42 
but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are 43 
unexplored. We investigated the association between UMs and CMR factors in individuals with 44 
different BMI and health status. Methods: UM was identified using UPLC-ESI-qToF-MS in 45 
individuals consuming pomegranate or nuts. The associations between basal CMR factors and the 46 
urine urolithin metabolomic signature were explored in 20 healthy normoweight individuals 47 
consuming walnuts (30 g/d), 49 healthy overweight obese individuals ingesting pomegranate extract 48 
(450 mg/d) and 25 metabolic syndrome (MetS) patients consuming nuts (15 g-walnuts, 7.5 g-49 
hazelnuts and 7.5 g-almonds/d). Results: Correlations between CMR factors and urolithins were 50 
found in overweight-obese individuals. Urolithin-A (mostly present in UM-A) was positively 51 
correlated with apolipoprotein A-I (P < 0.05) and intermediate-HDL-cholesterol (P < 0.05) while 52 
urolithin-B and isourolithin-A (characteristic from UM-B) were positively correlated with total-53 
cholesterol, LDL-cholesterol (P < 0.001), apolipoprotein B (P < 0.01), VLDL-cholesterol, IDL-54 
cholesterol, oxidized-LDL and apolipoprotein B:apolipoprotein A-I ratio (P < 0.05). In MetS patients, 55 
urolithin-A only correlated inversely with glucose (P < 0.05). Statin-treated MetS patients with UM-56 
A showed a lipid profile similar to that of healthy normoweight individuals while a poor response to 57 
lipid-lowering therapy was observed in MB patients. Conclusions: UMsare 58 
potentialCMRbiomarkers. Overweight-obese individuals withUM-B are at increased risk of 59 
cardiometabolic disease, whereas urolithin-A production could protect against CMR factors. Further 60 
research is warranted to explore these associations in larger cohorts and whether the effect of 61 
lipidlowering drugs or ellagitannin-consumption on CMR biomarkers depends on individuals’ UM. 62 
1. Introduction 63 
The gut microbiota is increasingly regarded as a key mediating factor in the development of obesity 64 
and cardiometabolic disorders [1]. Emerging evidence also indicates a potential relation between gut 65 
microbiota and certain chronic disease risk factors [1]. Previous reports correlate some gut microbial-66 
derived metabolites such as trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs) and 67 
hippurate with cardiovascular disease (CVD) risk in animal models [2,3]. Whether the real factor that 68 
correlates with CVD risk is the specific microbial metabolite and/or the gut microbial environment 69 
capable of producing such metabolite is not entirely understood. In this regard, the potential role of 70 
gut microbial metabolism of isoflavones in cardiometabolic risk has been previously suggested [4e6]. 71 
Indeed, the cardiometabolic risk seems to be different depending on individuals' isoflavone-72 
metabolizing phenotype, e.g. specific gut microbial environments capable of daidzein 73 
biotransformation to yield the metabolites O-desmethylangolesin (ODMA) and/or equol [5,7]. 74 
 Somehow parallel to the characteristic biotransformation of isoflavones, ellagitannins (ETs) and 75 
ellagic acid (EA) are also metabolized by the gut bacteria to give up some specific metabolites so-76 
known as urolithins [8]. This metabolism has been reported in humans and different mammals after 77 
consumption of ETs and EA rich foods such as some berries (strawberries, raspberries and others), 78 
pomegranates, walnuts and oak-aged wines, among others [8,9]. These bioavailable metabolites, 79 
mainly urolithin-A, exert antiinflammatory activities in vitro [10] and in vivo [8,11,12]. Urolithins 80 
were proposed as biomarkers of dietary ETs consumption [9] and had been identified as potential 81 
contributors to the favorable effects against CVD attributed to the consumption of pomegranates and 82 
other ET-containing foods [13]. As in the case of isoflavones, there is a considerable interindividual 83 
variability in the bioconversion of ETs to urolithins, which depends on the intestinal microbiota 84 
composition leading to three ETs-metabolizing metabotypes: ‘urolithin metabotype A’ (UM-A; only 85 
urolithin-A conjugates are produced), ‘urolithin metabotype B’ (UM-B; in addition to urolithin-A, 86 
isourolithin-A and/or urolithin-B are produced), and ‘urolithin metabotype 0’ (UM-0; urolithins are 87 
not produced) [14]. Although the three urolithin metabotypes (UMs) have been confirmed in different 88 
studies, weight gain and diseases linked to gut microbial imbalance (dysbiosis) favor the growth of 89 
bacteria able to produce isourolithin-A and/or urolithin-B rather than urolithin-A-producing bacteria 90 
[15]. Gordonibacter species (spp.) have the ability to transform EA into different urolithins in pure 91 
culture [16,17] and are positively correlated with urolithin-A in feces and urine, whereas occurrence 92 
of isourolithin-A and/or urolithin B are inversely correlated with fecal concentration of Gordonibacter 93 
spp. [18]. Higher plasmatic levels of urolithin-A recently have been described in individuals with less 94 
severe metabolic syndrome (MetS) traits because inverse correlations with both abdominal adiposity 95 
and impaired glycemic control were observed [19]. However, other critical urolithins and their 96 
association with relevant cardiometabolic risk blood lipid biomarkers have not yet been analyzed. To 97 
pursue the hypothesis supported by previous studies [14,15,18,19], we aimed to the study of UMs as 98 
metabolomic signatures involved in cardiometabolic risk. In this regard, we evaluated the association 99 
between UMs, BMI, glycemia, and serum lipoprotein-lipid profiles. Both healthy normoweight and 100 
overweight-obese groups of subjects were compared with MetS patients. 101 
2. Materials and methods 102 
2.1. Intervention studies and study products 103 
Human nutritional intervention studies were conducted in line with the Helsinki Declaration. The 104 
design of the trials including eligibility criteria for participants was previously reported in detail 105 
[18,20,21] (Fig. 1). In the first trial, healthy normoweight group (n = 20, 9 women and 11 men; BMI 106 
< 25 kg/m2) consumed 30 g per day of unpeeled walnuts for 3 days [18] (Fig. 1A). In the second trial 107 
(NCT01916239), overweight-obese healthy individuals (n = 49, 17 women and 32 men; BMI > 27 108 
kg/m2) without drug treatment, ingested 1 daily capsule of pomegranate extract (450 mg/day) for 3 109 
days. Capsules were kindly provided by Laboratorios Admira S.L. (Spain) [18] (Fig. 1B). In the third 110 
intervention study (ISRCTN36468613), 50 volunteers (28 men and 22 women; 35 with statins and 111 
15 without statins) with at least three MetS risk factors as defined by the Adult Treatment Panel III 112 
[20,21] were recruited in a prospective, randomized, controlled, parallel-designed and 12- week 113 
intervention feeding trial. Nut diet group (n = 25, 15 men and 10 women) consumed 30 g/d of raw 114 
unpeeled mixed nuts (15 g of walnuts, 7.5 g of hazelnuts and 7.5 g of almonds) (Fig. 1C). The nuts 115 
used in the study were donated by Borges S.A., Reus, Spain. 116 
 As our aim was to correlate blood cardiometabolic risk biomarkers with UMs, blood samples were 117 
collected before (baseline) the consumption of ET-containing foods, whereas both 24 h-urine and 118 
feces were collected after consuming the products (in order to stratify the volunteers according to 119 
their UMs). Total volume of urine was measured and the samples (urine and feces) were stored at -120 
80 ºC until they were analyzed. Blood samples were taken and rapidly centrifuged at 2,000g for 10 121 
min at 4 ºC. Serum and plasma EDTA aliquots were separated and stored at -80ºC until they were 122 
analyzed. 123 
2.2. Biochemical measurements 124 
Basal serobiochemical parameters were determined using automated biochemical auto-analyzers 125 
[21,22]. A quantitative determination of insulin was carried out using an IMMULITE 2000 analyzer 126 
(DPC, Los Angeles, California, USA). Fasting glucose and insulin values were used to calculate 127 
insulin resistance using the HOMA-IR method [22]. Non-HDL-cholesterol was calculated as total-128 
cholesterol minus HDL-cholesterol. Apolipoprotein A-I and B (ApoA-I and ApoB) were analyzed 129 
by immunonephelometry (Dade Behring, BN II, Marburg, Germany). HDL-cholesterol and 130 
LDLcholesterol subfractions were measured with a Lipoprint System (Quantimetrix, Inc., Redondo 131 
Beach, CA, USA). Densitometric reading and conversion to concentrations of lipoprotein classes and 132 
subclasses were carried out using the Lipoware software. We grouped HDL particles into ‘large’, 133 
‘intermediate’ and ‘small’ species and LDL into ‘large’ and ‘small’ particles. Cholesterol 134 
concentrations were determined [23]. VLDL-cholesterol and intermediate density lipoprotein (IDL) 135 
cholesterol concentrations were also obtained with the same assay system. The manufacturer's 136 
supplied reagents were used in each analysis. 137 
2.3. Chemicals 138 
Urolithins with a purity higher than 95% were obtained as described before [24]. 139 
2.4. Urolithin extraction and liquid chromatography-mass spectrometry (LC-MS) analysis 140 
Urine and feces were extracted as described before [24]. Briefly, urine samples (1 mL) were vortexed, 141 
centrifuged at 14,000g for 10 min at 4 ºC and the supernatant was filtered by using 0.45 mm PVDF 142 
filter. Fecal samples (1 g) were homogenized in 10 mL of methanol/DMSO/water (40/40/20) + 0.1% 143 
HCl, centrifuged at 3500g for 10 min and finally the supernatantwas filtered by using 0.45 mm PVDF 144 
filter. Ultra performance liquid chromatography-electro spray ionization-quadrupole time of flight-145 
mass spectrometry (UPLC-ESI-qToF-MS) was used for samples analysis as previously reported [24].  146 
2.5. Bacterial DNA extraction and real-time qPCR  147 
Powerfecal® DNA isolation kit (Mo-Bio Laboratories, Carlsbad, CA USA) was used according to 148 
the manufacturer's instructions for bacterial genomic DNA extraction. For Gordonibacter spp. 149 
quantification by real-time qPCR, specific primers were used as previously described [15,18]. 150 
2.6. Statistical analysis 151 
SPSS v. 19.0 (SPSS Inc, Chicago, USA) was used for statistical analyses. Comparisons among groups 152 
and UMs were carried out by a variance model (ANOVA) with the Bonferroni post hoc test. The 153 
association between two variables was measured with the Spearman correlation. Kendall correlation 154 
was used for the pairs, where isourolithin-A + urolithin-B concentration was one of the two variables. 155 
Statistical significance was recognized when P < 0.05. Discriminant principal component analysis 156 
(PCA) and plotted of groups were done using R with the github package. 157 
3. Results 158 
3.1. Serum lipids, glycemia and UMs 159 
Lipid and lipoprotein profile, plasma glycemia and urinary and fecal excretion of urolithin-A and 160 
isourolithin-A + urolithin-B after dietary ETs consumption were quantified in healthy normoweight, 161 
healthy overweight-obese and MetS groups (Table 1). Healthy overweight-obese individuals were 162 
considered in the same group because they showed a similar lipid profile (Fig. 2A). Totalcholesterol 163 
values were similar among healthy normoweight, healthy overweight-obese and MetS groups (Table 164 
1). Similar levels of triglycerides, total-cholesterol, LDL-cholesterol, non-HDLcholesterol and LDL-165 
cholesterol:HDL-cholesterol ratio were also found in both healthy overweight-obese and MetS 166 
groups. Only in MetS individuals using statins as lipid-lowering therapy (n = 14), LDL-cholesterol 167 
levels (3.24 mmol/L) were significantly lower (P = 0.045) than those in the overweight-obese group 168 
and similar to those of the normoweight group (data not shown). HDL-cholesterol concentrations 169 
were also lower in MetS than in overweight-obese individuals. Only plasma glucose, triglycerides: 170 
HDL-cholesterol and the total-cholesterol: HDL-cholesterol ratios were significantly higher in MetS 171 
than in overweight-obese individuals (Table 1). PCA of the current results identified two components 172 
accounting for 75% of the total variance. The first principal component (PC1) explained 49% of the 173 
variance and was determined by total-cholesterol, non-HDL-cholesterol and LDL-cholesterol. The 174 
second component (PC2) explained 26% of the variance and was represented mostly by HDL-175 
cholesterol, Gordonibacter spp. and glucose. The PCA plot illustrated that PC2, but not PC1, clearly 176 
differentiated between overweight-obese and MetS groups (P < 0.001) (Fig. 2A). Furthermore, fecal 177 
Gordonibacter spp. concentration positively correlated with HDL-cholesterol (r = 0.221; P = 0.032) 178 
and negatively with both plasma glucose (r =-0.320; P = 0.003) and VLDL-cholesterol levels (r = 179 
0.238; P = 0.027). On the other hand, both PC1 (P = 0.006) and PC2 (P = 0.027) discriminated among 180 
UMs (Fig. 2B). The differences in some serum markers were accentuated when normoweight and 181 
MetS individuals were compared. In this case, plasma glucose, triglycerides, HDL-cholesterol, non-182 
HDLcholesterol, as well as total-cholesterol:HDL-cholesterol, triglycerides:HDL-cholesterol, and 183 
LDL-cholesterol:HDLcholesterol ratios were statistically different between both groups (Table 1). 184 
Some differences between healthy normoweight and overweight/obese groups were also observed in 185 
serum markers, mainly in LDL-cholesterol, HDL-cholesterol concentrations and LDL-186 
cholesterol:HDL-cholesterol ratio (Table 1). The percentage of individuals with UM-B was higher in 187 
MetS (41%) than in overweight-obese (31%) and normoweight groups (20%) (Table 1). In contrast, 188 
the percentage of individuals with UMA was lower in those individuals with MetS (50%) than in 189 
overweight-obese (57%) and normoweight (70%) groups.  190 
3.2. Correlation between baseline serum markers and urolithins  191 
Healthy overweight-obese subjects with dyslipidemia but not subjected to any medical treatment 192 
were further investigated. Oxidized-LDL, ApoA-I, ApoB and cholesterol concentrations in various 193 
lipid subfractions from LDL and HDL were analyzed (Table 2). The main urolithins excreted in urine 194 
of overweightobese individuals after pomegranate extract consumption correlated with serum lipid 195 
markers (Table 2). Likewise, differences in serum lipid markers among UMs were also significant 196 
(higher levels of total-cholesterol, LDL-cholesterol and non-HDLcholesterol were observed in UM-197 
B than in UM-A in overweightobese individuals) (Fig. 3). In MetS individuals, the same tendency 198 
was observed, but the differences were only significant in those individuals under statin treatment 199 
(Fig. 3). Isourolithin-A + urolithin-B concentration in urine was positively correlated with total-200 
cholesterol (P < 0.001), LDL-cholesterol (P < 0.001), oxidized-LDL (P < 0.05), small LDL-201 
cholesterol (P < 0.05), large LDL-cholesterol (P < 0.05), ApoB (P < 0.01), VLDL-cholesterol (P < 202 
0.05), IDL (P < 0.05) and ApoB:ApoA-I ratio (P < 0.05), while urinary urolithin-A was positively 203 
correlated with ApoA-I and intermediate HDL (P < 0.05) in healthy overweight-obese individuals 204 
(Table 2). In MetS patients, urine urolithin-A levels only correlated inversely with plasma glucose 205 
(r=-0.537, P < 0.05) and glucose with total-cholesterol (r = 0.313, P < 0.05). No correlation was found 206 
between urine isourolithin- A + urolithin-B and plasma glucose or serum markers (data not shown). 207 
Fecal Gordonibacter concentration was positively correlated with urinary excretion of urolithin-A 208 
and negatively correlated with isourolithin-A + urolithin-B. However, serum lipid markers were not 209 
significantly correlated with fecal Gordonibacter concentration when healthy overweight-obese 210 
individuals were separately analyzed (Fig. 4). Correlation among serum lipids was also analyzed (Fig. 211 
4). In general, a positive correlation was demonstrated between total-cholesterol and LDL-212 
cholesterol, oxidized- LDL, LDL-cholesterol subfractions, non-HDL-cholesterol, small HDL-213 
cholesterol, IDL and ApoB. In contrast, HDL-cholesterol positively correlated with large HDL-214 
cholesterol and ApoA-I (P < 0.001) and negatively correlated with HOMA-IR (P < 0.05) and insulin 215 
(P < 0.05) (Fig. 4).  216 
4. Discussion 217 
Measurements of lipoprotein-lipid profiles together with blood pressure and glucose levels have been 218 
traditionally used to identify individuals at high risk of CVD [25]. However, the emerging role of the 219 
gut microbiota in CVD risk is giving rise to the development of new predicting CVD tools [26]. In 220 
this regard, we report here for the first time that ellagitannin-metabolizing phenotypes (e.g. UM-A or 221 
UM-B from gut microbiota) are useful as potential cardiometabolic risk biomarkers. There is 222 
increasing evidence that links UMs with gut dysbiosis and health status [15,18,19,27]. However, the 223 
possible association between urine urolithin metabolites and cardiometabolic risk had not yet been 224 
explored. In the present study, the percentage of individuals with UM-B was higher in overweight-225 
obesity and even more in those individuals with MetS. Notably, overweight-obese individuals with 226 
UM-B were at increased CVD risk, whereas UM-A seemed to be a protective metabotype against 227 
cardiovascular risk factors. Fecal Gordonibacter spp. levels were previously identified to be higher 228 
in UM-A individuals than in those with UM-B [15], which could be implicated in the protective effect 229 
of the UM-A. Our results on UMs and cardiometabolic risk are somehow parallel to those reported 230 
for isoflavones-metabolizing metabotypes. Similarly, Frankenfeld et al. [28] theorized that daidzein 231 
metabotypes could be useful as new biomarkers for evaluating disease risk. They found that the so-232 
called ODMA-producer metabotype, but not the equol-producer metabotype, was related with obesity 233 
in adults [5]. Recently, Hazim et al. [7] showed that the vascular benefits associated to the equol-234 
producer metabotype were related to the specific gut microbial environment rather than to the direct 235 
effect exerted by the metabolite equol. In the present study, we examined the correlation between 236 
UMs and a panel of serum lipids that provide an additional CVD risk criterion beyond classical target 237 
LDL levels. For example, it is known that persons treated with statins and target LDL levels, but with 238 
high either non-HDL or ApoB levels, remain at increased CVDrisk [25].We observed that differences 239 
between UM-A and UM-B, and total cholesterol and LDL-cholesterol values were significant only 240 
in overweight-obese individuals and MetS group under statin treatment but not in the MetS group 241 
free of statins. This is interesting and suggests that lipid-lowering treatments could be more effective 242 
in UM-A individuals. In overweight-obese individuals, additional serum markers such as oxidized-243 
LDL, ApoB and ApoA-I, which are increasingly used to provide optimal management of patients at 244 
moderate to increased CVDrisk [25,29],were also measured. Positive associations between several 245 
CVDrisk biomarkers (total-cholesterol, LDL-cholesterol, oxidized-LDL, small LDL-cholesterol, 246 
large LDL cholesterol, ApoB, VLDL-cholesterol, IDL and ApoB:ApoA-I ratio) and the excretion of 247 
isourolithin-A + urolithin-B were identified. ApoB is a more precise measure of the total atherogenic 248 
particles concentration than LDL-cholesterol concentration, since ApoB molecules are not only 249 
carried by LDL, but also by other atherogenic lipoproteins such as VLDL and IDL [25]. In the present 250 
study, ApoB concentration was highly correlated with non-HDL-cholesterol levels and according to 251 
previous research, it may help to identify coronary heart disease risk in a subpopulation of individuals 252 
with normal cholesterol levels [30]. The ratio of proatherogenic (ApoB) to antiatherogenic (ApoA-I) 253 
apolipoproteins (ApoB:ApoA-I) has been strongly associated with ischemic heart disease risk, even 254 
among individuals with a low total-cholesterol:HDL-cholesterol ratio [30]. Decreased LDL particle 255 
size is another CVD risk biomarker that is independent of LDL concentration [30]. Similarly, persons 256 
with low levels of either HDL-cholesterol or ApoA-I (the principal apolipoprotein on HDL particles) 257 
are also likely to experience CVD events, in spite of having normal LDL-cholesterol levels [25]. In 258 
the present study, urolithin-A was positively correlated with ApoA-I (P<0.05) in healthy overweight-259 
obese individuals. Some reports attribute to ApoA-I rather than to the overall number of HDL 260 
particles or their cholesterol contents, the anti-inflammatory and antioxidant properties of HDL 261 
particles [25]. It is known that inflammation participates in the link between obesity and metabolic 262 
diseases. In this regard, production of urolithin-A, a metabolite with strong in vivo anti-inflammatory 263 
activity could counteract the low-grade pro-inflammatory state associated with obesity and MetS. 264 
Therefore, as recently reported for equol [7], further research is warranted to elucidate the direct 265 
and/or indirect benefit associated to urolithin-A production in preventing CVD. Overall, our results 266 
suggest that healthy overweight-obese individuals with UM-B are at increased risk of 267 
cardiometabolic disease. Metabolic syndrome patients with UM-A and under statin treatment had a 268 
lipid profile like that of the healthy normoweight group while a poor response to lipid-lowering 269 
therapy was observed in UM-B patients. Therefore, in the new era of ‘personalized nutrition’, 270 
stratification of subjects in relation to their UMs could supply an additional tool for CVD risk 271 
assessment that must be replicated in large cohorts. In addition, further research is warranted to 272 
explore whether the impact of lipid-lowering therapy or dietary interventions with ellagitannin-273 
containing foods such as pomegranate or walnuts on cardiometabolic risk factors differs according to 274 
individuals' UMs. 275 
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